CVS Health
CVS
$104.43
-0.75%
CVS Health is a diversified healthcare company operating retail pharmacies, pharmacy benefit management (PBM) through Caremark, and health insurance via Aetna, serving approximately 9,000 stores, 2 billion adjusted PBM claims annually, and 27 million medical members. It is a vertically integrated healthcare giant, uniquely positioned at the intersection of pharmacy, insurance, and primary care following the Oak Street Health acquisition. The current investor narrative centers on a powerful turnaround driven by a lower medical cost ratio in its insurance segment, a favorable Medicare payment decision adding $13 billion in revenue, and raised full-year guidance, sparking debate on whether the rally is sustainable.…
CVS
CVS Health
$104.43
Related headlines
Investment Opinion: Should I buy CVS Today?
Rating: Buy. CVS Health is a compelling turnaround play with strong momentum, supported by a lower medical cost ratio, a $13 billion Medicare tailwind, and raised guidance. The consensus analyst rating is Strong Buy with an average target of $112.19, implying 4.1% upside, but the high target of $148 suggests significant potential if execution continues.
Supporting evidence: The forward P/E of 12.8x is attractive relative to the sector, and the P/S of 0.25x is a deep discount. Revenue grew 6.2% YoY in Q1 2026 to $100.4 billion, and net income swung from a loss to $2.94 billion. Operating margin improved to 4.7% from -3.1% in Q3 2025, and free cash flow of $7.4 billion TTM provides a 7.4% yield. The stock has outperformed the S&P 500 by 66.9 percentage points over the past year, confirming strong momentum.
Risks & Conditions: The biggest risks are a reversal in medical cost trends, regulatory changes to Medicare payments, and the high trailing P/E of 56.7x. This Buy rating would be downgraded to Hold if revenue growth decelerates below 5% or if the medical cost ratio rises unexpectedly. Upgrade to Strong Buy if the stock breaks above $110.68 (52-week high) with volume. Overall, CVS appears undervalued on a forward basis relative to its earnings power and peers.
Sign up to view all
CVS 12-Month Price Forecast
CVS Health is in the early stages of a powerful turnaround, with strong earnings momentum and a supportive regulatory catalyst. The forward valuation is attractive, but the trailing P/E of 56.7x and decelerating revenue growth warrant caution. The base case of a gradual recovery to $112 is most likely, but the bull case to $148 is achievable if execution exceeds expectations. The stance is bullish with medium confidence, as the key risk is whether the lower medical cost ratio can be sustained. An upgrade to high confidence would require another quarter of strong earnings and raised guidance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $113.50 and implied upside of +8.7% versus the current price.
Average Target
$113.50
0 analysts
Implied Upside
+8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $148
Analyst target range
CVS is covered by 26 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.5 on a 1-5 scale). The average target price is $112.19, implying 4.1% upside from the current price of $107.74. The distribution leans heavily bullish, with no sell ratings and a strong buy consensus, reflecting confidence in the turnaround. The target range spans from $79.00 (low) to $148.00 (high), a wide spread of $69, indicating significant uncertainty about the pace and magnitude of the recovery. The high target of $148 assumes successful execution on cost synergies from Oak Street Health and sustained lower medical costs, while the low target of $79 prices in potential margin compression or regulatory headwinds. Recent ratings from major firms (Wells Fargo, RBC, BofA, Morgan Stanley) have all been positive (Overweight/Buy/Outperform), with no downgrades in the past two months, reinforcing the bullish sentiment. The wide target spread suggests high uncertainty, but the consistent buy ratings signal strong conviction in the fundamental turnaround.
Drowning in data?
Find the real signal!
Bulls vs Bears: CVS Investment Factors
CVS Health presents a compelling turnaround story with strong momentum, but the investment debate hinges on whether the earnings recovery is sustainable. The bull case is supported by a powerful Q1 2026 earnings beat, a $13 billion Medicare tailwind, and a forward P/E of 12.8x that appears undemanding. However, the trailing P/E of 56.7x, decelerating revenue growth, and elevated debt levels temper enthusiasm. The single most important tension is whether the lower medical cost ratio can persist—if it does, the stock could re-rate toward the $148 high target; if costs revert, the stock could fall toward $79. Currently, the evidence slightly favors the bulls given the strong analyst consensus and improving fundamentals, but the wide target range underscores significant uncertainty.
Bullish
- Powerful earnings turnaround underway: Q1 2026 net income of $2.94 billion reversed a $3.97 billion loss in Q3 2025, driven by a lower medical cost ratio. EPS of $2.31 surged from -$3.13, demonstrating a dramatic operational recovery.
- Favorable Medicare payment boost: A CMS decision added $13 billion in revenue, significantly improving profit visibility. This catalyst drove the stock up 24% in May 2026 and underpins raised full-year guidance.
- Strong analyst consensus and upside: 26 analysts rate CVS a Strong Buy (mean 1.5/5) with an average target of $112.19, implying 4.1% upside. The high target of $148 suggests 37.4% potential if execution succeeds.
- Attractive forward valuation: Forward P/E of 12.8x is reasonable for a healthcare plan company, while P/S of 0.25x is a deep discount to typical managed care multiples of 0.5-1.0x. FCF yield of 7.4% is compelling.
Bearish
- Massive trailing P/E of 56.7x: Despite the turnaround, trailing P/E is 56.7x, reflecting that earnings are still recovering from a loss. Any setback in medical costs could compress the multiple sharply.
- Revenue growth deceleration trend: Q1 2026 revenue growth of 6.2% YoY is down from 9.5% in Q2 2025 and 7.0% in Q4 2025. Decelerating top-line growth may limit upside if cost improvements plateau.
- High debt and low current ratio: Debt-to-equity of 1.24x and current ratio of 0.84x indicate balance sheet strain. While FCF covers debt service, any earnings miss could heighten leverage concerns.
- Wide analyst target range signals uncertainty: Targets range from $79 to $148, a $69 spread. The low target implies 26.7% downside from current price, reflecting risk of margin compression or regulatory headwinds.
CVS Technical Analysis
CVS is in a sustained uptrend, with the stock up 83.4% over the past year, dramatically outperforming the S&P 500's 16.5% gain. The current price of $107.74 sits at 97.3% of its 52-week range ($58.99–$110.68), indicating strong momentum and near all-time highs, which can signal both bullish continuation and potential overextension. Short-term momentum is accelerating: the 1-month change of +5.8% and 3-month change of +38.2% both exceed the longer-term trend, with the 3-month gain far outpacing the S&P 500's 3.5%, confirming a powerful rally. The 1-month relative strength of 5.0% versus the market suggests continued buying pressure, though the stock's beta of 0.60 implies lower volatility than the market, which may temper sharp pullbacks. Key support lies at the 52-week low of $58.99, while resistance is at the 52-week high of $110.68; a breakout above $110.68 would signal a new leg higher, while a breakdown below recent support near $100 could indicate profit-taking. With a beta of 0.60, CVS is 40% less volatile than the S&P 500, making it a relatively defensive holding within healthcare.
Beta
0.60
0.60x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$61-$111
Price range past year
Annual Return
+68.2%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | +0.2% |
| 3m | +27.2% | +3.7% |
| 6m | +40.1% | +8.0% |
| 1y | +68.2% | +18.2% |
| ytd | +30.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue growth is steady but decelerating: Q1 2026 revenue of $100.4 billion grew 6.2% year-over-year, down from 7.0% in Q4 2025 and 9.5% in Q2 2025. The top line is driven by pharmacy revenue ($56.9B) and premiums ($33.8B), with front-store revenue ($5.3B) a smaller contributor. The deceleration reflects normalization after pandemic-era highs, but the absolute growth rate remains healthy for a large-cap healthcare firm. Profitability has improved markedly: Q1 2026 net income of $2.94 billion and EPS of $2.31 reversed a loss of $3.97 billion in Q3 2025, driven by a lower medical cost ratio. Gross margin of 15.6% is up from 12.8% in Q4 2025, though still below the 17.2% seen in mid-2021. Operating margin of 4.7% in Q1 2026 is a sharp recovery from -3.1% in Q3 2025, indicating the turnaround is gaining traction. The balance sheet is moderately leveraged: debt-to-equity of 1.24 and a current ratio of 0.84 suggest some liquidity tightness, but free cash flow of $3.4 billion in Q1 2026 (TTM $7.4 billion) provides ample coverage for dividends ($847M paid) and capex ($849M). ROE of 2.4% is low but improving from negative levels, and the FCF yield of 7.4% (based on market cap) is attractive.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Since net income is positive ($2.94B), the primary valuation metric is the P/E ratio. The trailing P/E is 56.7x, while the forward P/E is 12.8x, a massive gap that implies the market expects a sharp earnings recovery—consistent with the Q1 2026 turnaround. The forward P/E of 12.8x is reasonable for a healthcare plan company. Compared to the industry, CVS's P/S ratio of 0.25x is a deep discount to the sector average (not provided, but typical for managed care is ~0.5-1.0x), suggesting the market is pricing in skepticism despite the recovery. The EV/EBITDA of 18.8x is elevated relative to historical norms, reflecting the recent earnings rebound. Historically, CVS's trailing P/E has ranged from 7.8x (Q1 2026) to 227x (Q3 2024), and the current 56.7x is near the upper end of its recent range, but the forward multiple of 12.8x is near the lower end, indicating the market is pricing in normalized earnings. The P/B ratio of 1.34x is below the 5-year average of ~1.5x, suggesting the stock is not overvalued on a book value basis.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CVS's balance sheet carries moderate leverage with a debt-to-equity ratio of 1.24x and a current ratio of 0.84x, indicating potential liquidity tightness. While free cash flow of $7.4 billion TTM provides coverage, the net margin of only 0.4% in Q1 2026 (though improving) leaves little room for error. The operating margin of 4.7% is a sharp recovery from -3.1% in Q3 2025, but remains below historical levels, and any reversal in medical cost trends could quickly pressure profitability. Additionally, revenue growth is decelerating from 9.5% to 6.2% YoY, suggesting that top-line momentum alone cannot sustain the turnaround.
Market & Competitive Risks: CVS trades at a forward P/E of 12.8x, which is reasonable, but the trailing P/E of 56.7x leaves it vulnerable to multiple compression if earnings disappoint. The P/S ratio of 0.25x is a deep discount to typical managed care peers (0.5-1.0x), implying the market is pricing in skepticism. Regulatory risk is significant: the $13 billion Medicare payment boost could be reversed or adjusted in future rulemaking. Competition from UnitedHealth and Humana in the Medicare Advantage space remains intense. With a beta of 0.60, CVS is less correlated to the market, but sector rotation out of healthcare could still weigh on the stock.
Worst-Case Scenario: If medical costs rise unexpectedly, the earnings recovery could stall, leading to analyst downgrades and multiple compression. In this scenario, the stock could fall to the analyst low target of $79, representing a 26.7% decline from the current price of $107.74. The 52-week low of $58.99 would imply a 45.2% drop, but that level was reached during a period of losses and is less likely given the improved fundamentals. A realistic worst-case downside is approximately -27% to $79, consistent with the low analyst target.
FAQ
The key risks are: 1) Financial: High debt-to-equity of 1.24x and a low current ratio of 0.84x could strain the balance sheet if earnings falter. 2) Competitive: Intense competition from UnitedHealth and Humana in Medicare Advantage could pressure margins. 3) Regulatory: The $13 billion Medicare payment boost could be reduced in future rulemaking, and any changes to PBM regulations could impact Caremark. 4) Company-specific: The turnaround depends on sustaining a lower medical cost ratio; if costs revert to 2024 levels, EPS could fall sharply. The most severe risk is a 27% decline to the analyst low target of $79 if medical costs rise unexpectedly.
The 12-month forecast is moderately bullish, with a base case target of $105-$120 (50% probability), reflecting continued earnings recovery and stable medical costs. The bull case (30% probability) targets $120-$148, driven by better-than-expected cost savings and Medicare tailwinds. The bear case (20% probability) sees the stock falling to $79-$100 if medical costs rise or regulatory headwinds emerge. The consensus analyst average target is $112.19, implying 4.1% upside from the current price of $107.74. The most likely scenario is the base case, where the stock trades near $112 as the turnaround matures.
CVS is undervalued on a forward basis but appears overvalued on trailing metrics. The forward P/E of 12.8x is reasonable for a healthcare plan company and below the broader market, while the P/S ratio of 0.25x is a deep discount to typical managed care peers (0.5-1.0x). However, the trailing P/E of 56.7x reflects the recent earnings recovery from a loss, and the EV/EBITDA of 18.8x is elevated relative to historical norms. The P/B ratio of 1.34x is below the 5-year average of ~1.5x, suggesting the stock is not overvalued on a book value basis. Overall, the market is pricing in skepticism about the sustainability of the turnaround, creating a potential value opportunity if earnings continue to improve.
CVS Health is a good buy for investors with a moderate risk tolerance who believe the earnings turnaround is sustainable. The stock offers a forward P/E of 12.8x, a 3.4% dividend yield, and a consensus analyst target of $112.19 (4.1% upside). The biggest downside risk is a reversal in medical cost trends, which could push the stock to $79 (27% downside). For long-term investors, the combination of a low beta (0.60), strong FCF yield (7.4%), and a diversified healthcare model makes it an attractive holding. However, short-term traders should be cautious given the 83.4% rally over the past year and the stock's proximity to 52-week highs.
CVS is better suited for long-term investment given its low beta (0.60), 3.4% dividend yield, and diversified healthcare model that provides stability. The stock has risen 83.4% over the past year, so short-term traders may face profit-taking risk near 52-week highs. However, the forward P/E of 12.8x and FCF yield of 7.4% suggest upside over a 12-24 month horizon as the turnaround progresses. A minimum holding period of 12 months is recommended to allow the earnings recovery to fully materialize. Short-term traders could use technical levels, with support at $100 and resistance at $110.68, but the stock's low volatility may limit trading opportunities.
